PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial

D. Ramos-Barbon (Barcelona, Spain), N. Brienza (Barcelona, Spain), T. Bigorra Rodríguez (Barcelona, Spain), I. Gich Saladich (Barcelona, Spain), M. Puntes Rodríguez (Barcelona, Spain), R. Antonijoan Arbos (Barcelona, Spain), N. Castro Palomino Laria (Barcelona, Spain), J. Castro Palomino Laria (Barcelona, Spain)

Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Session: Asthma and cough: clinical trials and pharmacological insights
Session type: E-poster session
Number: 2279
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Ramos-Barbon (Barcelona, Spain), N. Brienza (Barcelona, Spain), T. Bigorra Rodríguez (Barcelona, Spain), I. Gich Saladich (Barcelona, Spain), M. Puntes Rodríguez (Barcelona, Spain), R. Antonijoan Arbos (Barcelona, Spain), N. Castro Palomino Laria (Barcelona, Spain), J. Castro Palomino Laria (Barcelona, Spain). PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial. 2279

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial
Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases
Year: 2020




Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine
Source: Eur Respir J 2002; 19: 611-616
Year: 2002



Elevated expression of adenosine A1 receptor in bronchial biopsy specimens from asthmatic subjects
Source: Eur Respir J 2008; 31: 311-319
Year: 2008



Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate (AMP) challenge
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

The adenosine A2A-Receptor is not involved in adenosine induced bronchoconstriction in asthmatics
Source: Eur Respir J 2003; 22: Suppl. 45, 103s
Year: 2003

Beyond the dogma: novel β2-adrenoceptor signalling in the airways
Source: Eur Respir J 2006; 27: 1286-1306
Year: 2006



Bronchoconstriction induced by inhaled adenosine 5'-monophosphate in subjects with allergic rhinitis
Source: Eur Respir J 2001; 17: 64-70
Year: 2001



An improved bronchial provocation test with dry powder adenosine instead of nebulised adenosine monophosphate (AMP)
Source: International Congress 2017 – Monitoring asthma control
Year: 2017

Effect of an inhaled adenosine A2A agonist on the allergen induced late asthmatic response
Source: Eur Respir J 2003; 22: Suppl. 45, 204s
Year: 2003

The role of CPA (adenosine A1 agonist) in airway reflexes
Source: Annual Congress 2004 - Neural regulation of airways and cough
Year: 2004


Effect of adenosine 5´-triphosphate (ATP) challenge vs. adenosine 5´-monophosphate (AMP) on the threshold of capsaicin-induced cough in healthy non-smokers, current smokers and patients with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 708s
Year: 2004

The bronchoprotective effects of levocetirizine on adenosine monophosphate challenge in patients with atopic asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 220s
Year: 2004

Adenosine 5’ – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in current smokers and patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 414s
Year: 2003

Cellular and gas exchange responses to adenosine 5‘-monophosphate (AMP) challenge in mild asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 442s
Year: 2004

The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016


Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids
Source: Eur Respir J, 50 (2) 1700670; 10.1183/13993003.00670-2017
Year: 2017



Dose response to budesonide using adenosine monophosphate (AMP) bronchial challenge: assessment of two dry powder inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 502s
Year: 2002

Adenosine 5' – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in healthy non-smokers and patients with mild asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 350s
Year: 2003

The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015

Effects of salbutamol on gas exchange abnormalities and sputum neutrophilia induced by adenosine 5‘-monophosphate (AMP) in mild asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 669s
Year: 2006